Your expert for minerals and nutraceuticals.






## Common Symptoms Experienced In Osteoarthritis (OA)

- **Pain:** Affected joints might hurt during or after movement.
- **Stiffness:** Joint stiffness might be most noticeable upon awakening or after being inactive.
- **Tenderness:** Your joint might feel tender when you apply light pressure to or near it.
- Loss of flexibility: You might not be able to move your joint through its full range of motion.
- **Grating sensation:** You might feel a grating sensation when you use the joint, and you might hear popping or crackling.
- Bone spurs: These extra bits of bone, which feel like hard lumps, can form around the affected joint.
- Swelling/Edema/Inflammation: This might be caused by soft tissue inflammation around the joint.





# Osteoarthritis (OA): Underlying Malfunctions In Joints



- joint pain loss of chondrocytes articular cartilage erosion synovial hyperplasia abnormal angiogenesis synovial inflammation subchondroal bone disturbance ligaments and tendons instability joint stiffness
- The to loss of articular cartilage.
- Breakage of cartilage components causes Inflammation.
- Promoted by inflammation due to cartilage degradation and loss of chondrocytes.
- Stimulated by inflammation.
- Increased levels of proinflammatory biomarkers IL-6, IL-1β, TNFα, MMP-3 and MMP-13.
  - **Overexpression of inflammatory cytokines** lead to subchondral disturbances.
  - Articular cartilage loss resulting from injury, overuse or repeating a movement over time. Contributes to osteoarthritis.

Results in reduced range of motion and physical function.






## Synergistic Approach For Optimal Joint Care

According to Research:

© Lehmann&Voss&Co. KG



4



## Pain associated with OA


- The most common symptom of OA is pain and associated stiffness in the affected joint which tends to worsen with joint movement.
- The **WOMAC** is a **valid and reliable** outcome measure in patients with OA.
- WOMAC OA index quantifies pain severity, joint stiffness and range of motion.

**Higher the score = Higher the pain severity** 



## Oxidative Stress in Osteoarthritis: The mechanism behind

- Superoxide anion is the most potent free oxygen radical (ROS), released during cartilage wear & tear and in OA.
- Superoxide release results in inflammation, tissue damage and pain.
- Cartilage degradation in turn releases more superoxide, setting up a vicious cycle.







# Oxidative Stress in Osteoarthritis: AmLexin<sup>™</sup> Potent Antioxidant Activity

	Superoxide Anion	
AmLexin™	12066	
Univestin™	4767	
Ginkgo Extract (24% flavonoids)	6768	
Resveratrol	266	
Citrus Bioflavonoids (20%)	0	

Against the most powerful ROS – the "Superoxide Anion".






# Pain in Osteoarthritis: Univestin<sup>™</sup> and AmLexin<sup>™</sup> Scientific Evidence



Univestin<sup>™</sup> results in effective pain relief, in as early as 5 days.



Fast acting, effectively alleviates pain with activity - hard activity.



AmLexin<sup>™</sup> led to 51% reduction in WOMAC pain scores over 12 weeks.

### **Combination Effect**

AmLexin<sup>™</sup> has a potent antioxidant effects against superoxide anions and Univestin<sup>™</sup> has powerful pain-relieving and anti-inflammatory qualities.

Combining Univestin<sup>™</sup> and AmLexin<sup>™</sup> potentially boost the pain relief effects.





# Combining with Univestin<sup>™</sup> and AmLexin<sup>™</sup> potentially boost pain relief

OA - Associated Pain	Univestin™	AmLexin™	Reference
Acute pain relief	$\checkmark\checkmark$	-	<u>Arjmandi <i>et al.</i></u>
Chronic pain relief	$\checkmark\checkmark$	$\checkmark\checkmark$	Kalman et al., Sampalis et al.

#### TABLE 1: Percentage changes in pain sensitivity for MIA- Induced rats treated with AmLexin<sup>TM</sup>, Univestin<sup>TM</sup> and their combination.

Group	Dose (mg/kg)	Ν	Wk 1	Wk 2	Wk 3	Wk 4	Wk 5
% increase							
MIA	10	10	$44.9^{\dagger}$	$45.4^{\dagger}$	47.7 <sup>†</sup>	$46.5^{\dagger}$	47.1 <sup>†</sup>
% inhibition							
Diclofenac	10	10	49.6 <sup>†</sup>	34.5 <sup>†</sup>	34.3*	35.5 <sup>†</sup>	$34.9^{\dagger}$
AmLexin™	400	10	21.1*	28.3*	33.0 <sup>†</sup>	37.0 <sup>†</sup>	$38.0^{\dagger}$
Ü∎-bś {ĕ ∎™	250	10	35.5*	33.8 <sup>†</sup>	38.1 <sup>†</sup>	43.3 <sup>†</sup>	$45.9^{\dagger}$
Composition <sup>‡</sup>	650	10	$59.6^{\dagger}$	$64.6^{\dagger}$	$70.7^{\dagger}$	69.9 <sup>†</sup>	$70.3^{\dagger}$


\* $P \le 0.00001$  verses MIA;  $^{\dagger}P \le 0.000001$  verses MIA or normal control; % increase = ((mean normal control – mean MIA)/mean normal control) \* 100; % inhibition = ((mean treatment – mean MIA)/(mean normal control – mean MIA)) \* 100. \*Composition: AmLexin<sup>TM</sup> + Universitin<sup>TM</sup>






## Stiffness in Osteoarthritis

- Joint inflammation and oxidative stress are **directly** associated with OA progression.
- Joint stiffness might be most noticeable upon waking up or after being inactive.






L



## Stiffness in Osteoarthritis



Significant reduction in joint stiffness within 3 days of use of Univestin™.



Day - 3 Day - 5 Day - 7



### 45% reduction in WOMAC stiffness scores.

### **Remember:**

AmLexin<sup>™</sup> has highest ORAC value for Superoxide Anion (ORAC: 12066).



# Stiffness in Osteoarthritis

Stiffness	Univestin™	AmLexin™	References
Relief from joint stiffness	$\checkmark\checkmark$	$\checkmark\checkmark$	<u>Arjmandi et al.</u> , <u>Kalman et al.</u>
Increased Reactive oxygen species (ROS)	$\checkmark\checkmark$	$\checkmark\checkmark$	<u>Yimam et al.</u>








# Loss of function and flexibility in Osteoarthritis

# Meaning: 90° 140° • Not being able to move the joint through its full range of motion. 45° 20° Real-time feedback 10° Isokinetic Dynamometer 0°








## Loss of flexibility in Osteoarthritis: Univestin<sup>™</sup> and AmLexin<sup>™</sup> Benefits





### Univestin<sup>™</sup> significantly improves range of motion.





Extension change	1.65 ± 2.43 (43)
from baseline to	0 (-1-10)
day 84	$p < 0.001^*$
Flexion change	$-8.3 \pm 7.1$ (43)
from baseline to	-8 (-25-8)
day 84	$p < 0.001^*$
* Significants p < 0.05	

\*Significant:  $p \leq 0.05$ .




# Loss of function in Osteoarthritis: Univestin<sup>™</sup> Benefits






6- minute Walk Difference Day 0 to Day 7 in meters







## Joint Compression: Univestin<sup>™</sup> and AmLexin<sup>™</sup> Benefits



Univesti

Yimam M et al. (2017) Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu, Evid Based Complement Alternat Med. 2017 Aug 20:2017:7059068. doi: 10.1155/2017/7059068

# Joint function and Range of Motion(RoM)

Joint Function and Flexibility	Univestin™	AmLexin™	References
Improved joint function and RoM	$\checkmark\checkmark$	✓	<u>Arjmandi et al.</u> , <u>Kalman et al.</u> , <u>Yimam et al.</u>







# COX/LOX inhibition for Quelling Inflammation: Concerns

Non selective COX inhibition leads to gastric disturbances due to COX-1 inhibition while selective COX-2 inhibition may cause cardiac side effects.

Blocking the COX pathway(s) shunts more AA metabolism down the 5-LOX path  $\Rightarrow$   $\uparrow$  highly chemotactic and inflammatory leukotrienes.

These effects are mediated through LTB4 which is:

- Associated with increased production of the pro-inflammatory cytokines.
- Shown to stimulate osteoclastic bone resorption.
- Detected at high levels in the walls of NSAID induced gastric ulcers.






# Joint Swelling and Inflammation: Univestin<sup>™</sup> and AmLexin<sup>™</sup> Synergy

Univestin<sup>™</sup> and AmLexin<sup>™</sup> demonstrate dual **COX and LOX** inhibition of systemic inflammation and reduce **ROS** enabling a holistic control of **all four** AA metabolism **pathways**.

Burnett et al., (2007) <u>A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a</u> <u>dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation</u>, J Med Food. 10(3):442-51.

Yimam et al., (2016), <u>UP1306, a Botanical Composition with Analgesic and Anti-inflammatory</u> <u>Effect</u>, Pharmacognosy Res. 2016 Jul-Sep;8(3):186-92.





# Counters swelling and inflammation by 'Dual Mechanism'

Swelling and Inflammation	Univestin™	AmLexin™	References	
COX-1 & COX-2 inhibition	$\sqrt{\sqrt{2}}$	✓	<u>Burnett et al.</u> , <u>Yimam et al.</u>	
5-LOX inhibition	✓	$\sqrt{\sqrt{2}}$		







# Joint Swelling and Inflammation: Univestin<sup>™</sup> and AmLexin<sup>™</sup> Synergy

### The Double Advantage of Combining Univestin<sup>™</sup> + AmLexin<sup>™</sup>:

**Univestin™** and **AmLexin™** tackle the **pro-inflammatory biomarkers (IL-6, 1β, TNFα)** while **AmLexin™** further reduces **proteolytic enzymes (MMP3 and MMP13)** - both of these are involved in inflammation and articular cartilage degradation.


		Univestin™	AmLexin™
Pro-inflammatory Biomarkers Suppression	IL-6	$\checkmark$	<b>\ \ \</b>
	ΙL-1β	$\checkmark$	<b>\ \ \</b>
	ΤΝFα	✓	<b>\ \ \</b>
Cartilage Degradation Biomarkers Suppression	ММРЗ	-	$\checkmark\checkmark$
	MMP13	-	$\checkmark\checkmark$







## Joint Cartilage Degradation in Osteoarthritis




### GAG and uCTX-II:

Two main biomarkers for joint cartilage degradation.




# Joint Cartilage Degradation in Osteoarthritis: AmLexin<sup>™</sup> Benefits on Cartilage Degradation

 AmLexin<sup>™</sup> reduced IL-1α mediated degradation of Glycosaminoglycans (GAG) from proteoglycan of joint cartilage.



• AmLexin<sup>™</sup> significantly **reduces uCTX-II levels** over placebo in subjects with knee osteoarthritis.




### Treatment Conc.



## Synergistic effect of Univestin<sup>™</sup> + AmLexin<sup>™</sup> on Cartilage Protection


- Injection of **Mono-IodoAcetate (MIA)** into rats' femorotibial joint triggers limb pain and progressive cartilage degradation, establishing an **osteoarthritis (OA) model akin to human OA.**
- In vivo, AmLexin<sup>™</sup> + Univestin<sup>™</sup> treated rats exhibit marked preservation of articular structure, evidenced by histopathological findings (image on next slide).
- In contrast, diclofenac failed to significantly protect cartilage, highlighting NSAIDs' limitation in OA treatment, mainly offering symptomatic relief without disease-modifying effects.

Yimam M et al. (2017) Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu, Evid Based Complement Alternat Med. 2017 Aug





## Synergistic effect of Univestin<sup>™</sup> + AmLexin<sup>™</sup> on Cartilage Protection



**MIA + Combination** 







# Chondroprotection: AmLexin<sup>™</sup> Benefits

Parameters of joint degradation	Univestin™	AmLexin™	References	
Glycosaminoglycans (GAG)	-	$\checkmark\checkmark$		
Increased uCTX-II	-	$\checkmark\checkmark$	<u>Kalman et al.</u> , <u>Yimam et al.</u>	







# Take Away: Synergy 1 + 1 = 11

- According to Research, the combination of Univestin<sup>™</sup> and AmLexin<sup>™</sup> shows to provide greater pain relief and cartilage protection.
- This combination also shows to reduce associated symptoms by enhancing the anti-inflammatory and analgesic action of Univestin<sup>™</sup> with the cartilage degradation support from AmLexin<sup>™</sup>.

Alleviation of OA Signs and Symptoms	Univestin™	AmLexin™
Pain	$\sqrt{\sqrt{\sqrt{2}}}$	$\checkmark$
Stiffness	$\sqrt{\sqrt{2}}$	$\sqrt{}$
Swelling and Inflammation	$\sqrt{\sqrt{2}}$	$\checkmark$
Range of Motion	$\sqrt{\sqrt{2}}$	$\checkmark$
Joint Cartilage Degradation	$\checkmark$	$\sqrt{\sqrt{\sqrt{2}}}$
ROS - Superoxide Anion	$\checkmark$	$\sqrt{\sqrt{\sqrt{2}}}$



# The Complete Optimal Joint Care Solution









## Talk to the experts

### Find here your sales representative in Europe

For details about our ingredients register to our digital platform:

WEBAPP

### Visit our website <u>lehvoss-nutrition.com</u>

For any other enquiry contact:

marketing@lehvoss.co.uk



LEHVOSS Nutrition UK 40 Holmes Chapel Road Congleton Cheshire SW12 4NG

P: +44 (0) 1260 691 000 E: marketing@lehvoss.co.uk www.lehvoss-nutrition.com Lehmman&Voss&Co. KG Alsterufer 19 20354 Hamburg

Court of registration: Hamburg Local Court Registration number: HRA 39518 VAT ID No.: DE 118262854

Shareholders authorized to represent the company: Knut Breede, Dr. Thomas Oehmichen, and Soenke Thomsen



www.lehvoss.de

Any recommendations made for use of the Seller's materials are made to the best of the Seller's knowledge and are based upon prior tests and experience of the Seller believed reliable; however, Seller does not guarantee the results to be obtained and all such recommendations are non-binding – also with regard to the protection of third party's rights, do not constitute any representation, and do not affect in any way the Buyer's obligation to examine and/or test the Seller's goods with regard to their suitability for the Buyer's upposes.

No information given by the Seller is to be construed in any way as a guarantee regarding characteristics or duration of use, unless such information has been explicitly given as a guarantee. This email and any attached files are confidential and intended for the use of the individual to whom they are addressed.

